Visceral leishmaniasis: a common cause of post-infectious febrile pancytopenia in children in an endemic area: experience of a children's tertiary hospital

Pediatr Emerg Care. 2012 Jun;28(6):533-7. doi: 10.1097/PEC.0b013e3182587d5d.

Abstract

Background: Visceral leishmaniasis (VL, kala-azar) is caused by Leishmania spp, a parasite that is commonly encountered in Mediterranean countries. Leishmaniasis usually presents with fever, hepatosplenomegaly, lymphadenopathy, and pancytopenia.

Objectives: The aim of the study was to prospectively examine the characteristics of cytopenia associated with VL and compare it with other post-infectious cytopenias observed in children with febrile illnesses.

Methods: We studied 112 children, aged (mean) 4.0 (SD, 3.8) years (range, 0-14 years), who were admitted to the pediatric ward because of febrile cytopenia associated with infections, during a 2-year period (March 2005 to June 2007). Study participants were investigated with measurement of acute-phase reactants, bacterial cultures, and serologic tests.

Results: Pancytopenia was detected in 9 (8%) of 112 patients (5 boys), with a mean age of 4.5 (SD, 3.0) years.The mean value of white blood cell was 3827 (SD, 1455)/mL; absolute neutrophil count, 1229 (SD, 655)/mL; hemoglobin, 8.3 (SD, 1.1) g/dL; and platelet count, 88,200 (SD, 20,186)/mL. All patients with pancytopenia had fever (mean duration, 8.9 [SD, 8.7] days) (maximum temperature, 39.5°C [SD, 0.6°C]) and hepatosplenomegaly (9/9), whereas 2 of 9 had lymphadenopathy. In these patients, a bone marrow aspiration was performed, and VL was detected in all 9 samples. They were treated with liposomal amphotericin B and had an excellent response rate. Pancytopenia resolved within a mean period of 17.6 (SD, 17.3) days (range, 8-60 days), and there was no relapse during a 2 years' follow-up.

Conclusions: In endemic countries, leishmaniasis is the main cause of febrile pancytopenia among children in whom hematologic malignancy has been ruled out.

MeSH terms

  • Adolescent
  • Amphotericin B / therapeutic use
  • Antiprotozoal Agents / therapeutic use
  • Child
  • Child, Preschool
  • Communicable Diseases / complications
  • Communicable Diseases / epidemiology
  • Endemic Diseases*
  • Female
  • Greece / epidemiology
  • Humans
  • Infant
  • Infant, Newborn
  • Leishmaniasis, Visceral / complications*
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / epidemiology*
  • Male
  • Pancytopenia / epidemiology*
  • Pancytopenia / parasitology*
  • Prospective Studies

Substances

  • Antiprotozoal Agents
  • liposomal amphotericin B
  • Amphotericin B